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Abstract 
 Recent advancements in cancer research has led to the synthesis of a new drug known as 
docetaxel. Meant to replace paclitaxel, its more natural counterpart whose ingredients are difficult 
to obtain, the drug is known to effectively treat a wide array of cancers, including breast cancer, 
ovarian cancer, and prostate cancer. The establishment of a synthetic alternative to paclitaxel has 
increased its bioavailability, thereby lowering the cost needed to utilize the drug. Still, the limiting 
factor in minimizing costs is the method in which the drug is processed. Current methods in drug 
processing have their limitations, which include the introduction of impurities and a low effective 
yield due to poor powder geometry. Thus, the goal of this study looks to explore a new way to 
process the drug in a more efficient manner. 
 In this study, a new method for processing docetaxel is explored on in great detail. A more 
direct method of using electrospray deposition is utilized for the creation of monodisperse 
nanoparticles, with the main intention of increasing the efficiency at which the drug is processed 
and prepared for drug delivery to the patient by means of injection. A key feature in electrospray 
deposition is its ability to produce droplets that are sized homogenously. These droplets eventually 
evaporate at homogenous rates. These two concepts have been exploited to consistently produce 
nanoparticles of the cancer drug, which is made possible by the fact that the minimal variation in 
droplet sizes has easily translated to minimal variation in dry particle sizes. Compared to other 
methods of drug processing, one other benefit that electrospray deposition conveys is that through 
evaporation, virtually all impurities and unwanted foreign material are eliminated. 
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 Moreover, a binary solvent system is investigated in more detail in this study, so as to 
determine its effects on both the evaporation of the solvent and the diffusion of the drug into 
nanoparticles. From there, material and geometric properties of the electrospray nozzle were 
explored upon in great detail, with the main goal of being able to produce a cone jet that 
consistently dissociates into monodisperse droplets. At the same time, controllable properties of 
the electrospray atomizer were investigated and continuously modified. Modifications in both the 
components of the solution and the operating temperature were also considered to enhance both 
the electrospray deposition process and the geometry of the particles. Scanning electron 
microscopy (SEM) characterization is continuously utilized to determine suitability of results 
obtained in experiments. 
 Ultimately, the goal of this study is to determine the ideal conditions (solvent ratios, flow 
rate, operating temperature, electrospray atomizer nozzle configurations, etc.) in which spherical 
docetaxel particles sized at 100-200 nm can be produced. 
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Chapter One: Biochemical Background 
1.1. Introduction 
 Recent advancements in pharmaceutical research has led to the creation of a wide array of 
drugs capable of treating different cancers. While these drugs do destroy tumors, the effectiveness 
at which they do so can be largely hampered on the nanoscale level by which the drugs have been 
processed. Inconsistencies in particle geometry can lead to issues such as improper drug intake 
and reduced effectiveness of treatment. This study attempts to circumvent such issues by using 
electrospray deposition as the conduit for which particles with more consistent geometry can be 
produced. 
 This contribution primarily focuses on docetaxel as the model drug, with occasional 
experiments being performed on a similar drug known as paclitaxel. The two drugs behave 
similarly when it comes to treating diseases such as breast cancer and prostate cancer. 
 Bioavailability 
 Paclitaxel was originally the first-choice drug for treating cancers. It is primarily obtained 
from the bark of the Pacific Yew tree in the form of an extract. However, due to the scarcity of the 
source tree, docetaxel has been artificially synthesized to serve as a less expensive substitute, and 
has therefore been more easily marketed than its natural counterpart. (1) 
 Additionally, studies were conducted to determine if there were differences in the efficacies 
of the two drugs. Researchers were able to prove that docetaxel exhibits more effectiveness in 
treating the same cancers. (2-4) 
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1.2. Background 
 Mechanism Overview 
 Like most cancer drugs, docetaxel treats breast and prostate cancer through multiple 
different fronts. These can include inhibiting tumor growth, preventing the division of the infected 
cell, preventing transmittance to other cells, and even outright destroying the infected cell. 
 However, before combatting the tumor, the drug is to naturally be first taken to the cancer 
site. Docetaxel is primarily distributed as a drug dissolved in an alcoholic solution, and is to be 
injected into the patient by means of a needle. From there, cells in the body transport the drug 
eventually to the cancer site by means of natural circulation. (5) 
 Morse, Gray, et al, determined that the main mechanism at which docetaxel functions is 
through a process known as mitotic catastrophe. Here, docetaxel disrupts mitosis by first disrupting 
the division of the chromosomes. From there, cell division does occur, but the new cells contain 
poorly-structured nuclei and significantly-shrunk cytoplasm, thereby rendering them unable to 
reproduce and spread the cancer elsewhere. Ultimately, the unhealthy cells, which are severely 
damaged at this point, eventually die out. (6) 
 Surfactants 
 To facilitate such a process, the additive D-α-tocopheryl polyethylene glycol succinate, 
better known as vitamin E TPGS, is introduced to the solution of the drug as a surfactant. The 
surfactant has a wide array of purposes, ranging from increasing the solubility of the docetaxel 
itself to increase the efficiency of the drug delivery process. 
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 In the chemical context, docetaxel on its own has an extremely low threshold for solubility 
due to its molecular structure. This is largely due to polarity; docetaxel molecules exhibit minimal 
dipole moment, as presented in the bond-line structure shown in Figure 1 below. (7) 
 
Figure 1: Molecular structure of docetaxel. 
 As shown in the structure, docetaxel contains two aromatic rings, as well as a non-
elongated core. These two substituents, as well as a central nine-membered bridged ring, minimize 
the overall polarity of the drug, thus rendering it insoluble to the organic solvents used in this 
study. Consequently, the introduction of vitamin E TPGS increases the solubility of the drug in 
increasing polarity. This is achieved through a unique structure, shown below in Figure 2. (8) 
 
Figure 2: Structure of vitamin E TPGS, which contains both polar and nonpolar components. 
4 
 
 Fundamentally, vitamin E TPGS contains both polar and nonpolar components. Solubility 
is increased in that the nonpolar core affixes onto the drug molecules, while the polar tails are used 
to increase attraction towards the solvent.  
 The introduction of vitamin E TPGS also increases the efficacy at which the drug treats the 
cancer cells. Zhang, Tan, et al, was able to demonstrate this by conducting experiments that 
compared the degradation rates of TPGS-emulsified docetaxel to that of docetaxel without 
modifications. These degradation rates, in turn, reflect the strength of the drug upon reaching the 
tumor. A higher concentration over a longer time period implies that the drug did not severely 
degrade during the transport process. The longer durability of the TPGS-emulsified docetaxel in 
Figure 3 shows that vitamin E TPGS is an excellent conduit for ensuring that the docetaxel is 
effective in its purpose. (8) 
 
Figure 3: Degradation of docetaxel (commercially marketed as Taxotere) as compared to docetaxel 
emulsified with TPGS (indicated by NP). 
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 Stipulations 
 In general, the effectiveness of the treatment is largely limited to the geometry of the 
powders formed during processing. In order for the drug to be able to be able to bypass the immune 
system and be transported to the site of the tumor by means of cellular processes, its powders must 
be of a spherical shape ranging approximately 100-200 nm. 
 Such stipulations are put in place in that there are adverse effects when deviations from the 
recommended geometry are present. For instance, particles that are too large (i.e. a diameter greater 
than 200 nm) are more likely to be rejected by the immune system, which can mistake the drug for 
foreign matter. (9) On the other hand, in spite of particles smaller than 100 nm being able to easily 
bypass such defenses, a smaller size significantly inhibits the efficiency at which the drug is 
encapsulated. (10-11) Thus, particles in the optimal size range of 100-200 nm will be able to not 
only avoid rejection, but also be able to successfully prevent the growth of the tumor. 
 Lastly, a perfectly spherical particle geometry is necessary for the surfactant to form 
micelles around the nanoparticles, a necessary step in making possible the delivery of the drug to 
the cancer site without unintentionally damaging innocent cells. 
 Thus, this contribution largely focuses on using a binary solvent system and electrospray 
deposition as a technique to achieve such a desired particle morphology. 
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1.3. Current Drug Processing Techniques 
 Currently, there are different methods of preparing the drug for delivery in achieving such 
a particle morphology, but each one has its set of drawbacks, ranging from low yield to high 
process complexity. 
 Wet Milling 
 One possible method for processing the drug is through wet milling. Originally, wet milling 
was considered as the ideal method for processing docetaxel in that dissolution through a solvent 
was not needed. Instead, the drug is placed in bulk inside a milling chamber along with milling 
pearls. Both the pearls and the bulk drug are spun at high revolution rates. Through collisions with 
the pearls, the walls of the chamber, and other drug particles, the drug is eventually reduced into a 
set of superfine particles. 
 While the wet milling might seem attractive due to its ability to generate nanoscale particles 
of poorly soluble drugs with consistent geometry, the main risk with such a processing method is 
that it can lead to contamination from the pearls. During the milling process, the pearls may be 
damaged due to the violent collisions, and pieces of the oftentimes ceramic material may mix in 
with the drug and do so undetected. Additionally, the yield generated from such a process is 
relatively poor. (11-12) 
 Precipitation 
 A simpler way of processing docetaxel is through a process known as precipitation. Here, 
the drug is simply dissolved in a solvent-antisolvent pair (i.e. two complementary, but immiscible 
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solvents). Miscibility between the two solvents and the solubility of the drug in the solvent pair is 
forced through sonication or constant stirring. Through nucleation, nanoparticles quickly form at 
the conclusion of the process. 
 Here, the main limiting factor is that there is little to no control when it comes to achieving 
the desired particle geometry. Consequently, the effective yield attained in such a process is 
severely minimized, and filtering out the correct particles is a laborious process on its own. (13) 
 Coaxial Electrospray Deposition 
 Other research groups such as Cao, Luo, et al, did in fact attempt to use electrospray 
deposition as a technique for processing bulk paclitaxel into fine powders (which can be translated 
into processing docetaxel). (14) However, they did so in an indirect manner, using a system 
consisting of coaxial nozzles. Each of the three nozzles deposited one of the following 
components: a core (the drug), a shell, and a corona. Figure 4 demonstrates the process in which 
electrospray deposition was used as a tool for generating nanoparticles of paclitaxel. 
 
Figure 4: Schematic diagram of the coaxial electrospray method to produce monodisperse nanoparticles, 
followed by the removal of the corona. 
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 Here, electrospray deposition was used to generate tri-layered particles. A suspension 
system was then used to eliminate the corona. The drug and its accompanying polymeric shell was 
then filtered from the colloid. (14) 
 While this method does produce nanoparticles with consistent geometry and with no effect 
on the capabilities of the drug, its main drawback is the low yield that is achieved due to the 
stipulation of separating the corona from the core and the shell. Thus, in this study, a more direct 
method of using the electrospray for the purpose of the drug delivery of docetaxel is investigated.  
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Chapter Two: Electrospray Fundamentals 
2.1. Motivation 
 The main purpose of this study is to be able to determine the optimal conditions for which 
the electrospray can be used to process a cancer drug known as docetaxel. The idea is to dissolve 
bulk amounts of docetaxel in a binary solvent system, and from there use the capabilities of 
electrospray atomization to produce monodisperse droplets. These droplets then evaporate in a 
two-stage manner: first quickly, followed by a much slower evaporation to gain control over the 
particle re-formation process of the solid docetaxel drugs.  
 In doing so, the aim is to demonstrate that electrospray deposition is an excellent conduit 
for increasing the efficiency of the drug delivery process, as well as to maximize the amount of 
usable yield by being able to homogenize the geometry of the drug particles in terms of both size 
and shape. Particle geometry is important with regards to increasing the likeliness of the body’s 
acceptance of the drug and its transportation to the site of the tumor. 
 
2.2. Overview of Electrospray Deposition 
 Jet Formation 
 Fundamentally, electrospray deposition works by having an extremely narrow pipe known 
as a capillary (order of microns or millimeters) that is open on one end, wherein the exposed end 
faces a deposition plate in an orthogonal manner. This opening is spaced away from the deposition 
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area by merely a few centimeters. The capillary, which either has a metallic segment connected to 
a non-metallic material (e.g. silica) or is entirely metallic, is connected to a high voltage source.  
 During operation, the liquid solution flows through the pipe from a syringe by means of a 
pump or pressurized gas. The high-voltage source, which is connected to the metallic segment of 
the capillary, provides electric charge to the solution itself by introducing a potential difference in 
the order of kilovolts (kV). As a result, the solution is drawn towards the center of what is known 
as a cone jet, wherein a narrow column of the fluid is formed. (15) 
 Eventually, this column dissociates into a series of droplets, which evaporate quickly due 
to the extremely small surface area. If the solution contains solutes that are normally solid at the 
established operating temperature, their particles fall onto a grounded collection plate, which can 
have a small collection chip in the form of aluminum foil or a piece from a silicon wafer. Figure 5 
illustrates the process, starting from the pumping of the liquid all the way to the collection of dry 
particles on a grounded surface. (15) 
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Figure 5: Simple schematic of electrospray deposition. 
 Jet Stability 
 With regards to operating an electrospray atomizer, multiple facets could be adjusted, each 
one yielding different results. Typically, parameters such as inner diameter nozzle, applied voltage, 
flow rate, and, in some cases, the operating temperature are adjusted to accommodate the user’s 
desired deposition behavior. 
 Regardless of other parameters, it is oftentimes the applied voltage that dictates what mode 
of deposition is generated. Typically, electrospray deposition involves three modes: first, the 
dripping mode, wherein extremely large droplets are created without the involvement of a cone 
jet. The stable cone jet mode entails one cone-shaped jet being formed and breaking up into a 
successive series of droplets that are both smaller and more consistently-sized. Lastly, the multi-
jet mode entails behavior similar to that of fire sprinklers, wherein multiple jets are formed, each 
one successively disintegrating into much smaller droplets. These three behaviors are achieved 
through different levels of applied voltage, which is tabulated in Table 1. (15) 
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Applied Voltage Range (kV) Electrospray Behavior 
0 – 2  Dripping Mode 
2 – 3 Stable Cone-Jet Mode 
3 – 15 Multi-Jet Mode 
Table 1: Electrospray behaviors at different levels of applied voltage. 
 While applied voltage dictates behavior, finer control of droplet and dry particle sizes could 
be achieved by varying both the flow rate and the inner diameter of the nozzle. In general, droplet 
size is directly proportional to both flow rate and nozzle inner diameter. Past studies have proposed 
different scaling laws. Zarrabi and Vossoughi, for instance, proposed that 
𝑑𝑝 = (
𝜌𝑠𝑤
𝜌𝑠𝑤+𝜌𝑝(1−𝑤)
𝑑3)
1
3
   
where dp is dry particle size, d is the droplet size, w is the weight fraction of the solid solute in the 
liquid solvent, ρs is the density of the solvent, and ρp is the density of the solid solute. (16) 
 For binary solvent systems, the density of the solvent can be defined as 
𝜌𝑠 = 𝜌1𝑉1 + 𝜌2𝑉2 
where ρ1 and ρ2 are the densities of the two solvents, and V1 and V2 are their respective volume 
percentages 
 Additionally, for droplet size, Deng, Gomez, et al, proposed that 
𝑑 = 𝐺(𝜖) (
𝑄𝜖𝜖0
𝛫
)
1
3
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where G(ϵ) is a function relatively close to unity, Q is the flow rate, ϵ and ϵ0 are relative 
permittivities of the fluid and of free space, respectively, and Κ is the fluid conductivity. (15)  
 Wetting 
 During experimentation, it has been discovered that one way that a stable jet could be 
disrupted is through a phenomenon known as wetting. Here, the surface tension of the solution 
dominates over the electromotive force necessary to break the jet of the solution up into 
monodisperse droplets. Consequently, the jet of the solution sticks to the outer walls of the nozzle, 
where more energy is required to produce the droplets. Due to the higher force requirement, larger 
droplets are sometimes produced. In terms of morphology, this translates to drug particles that 
have inconsistent size and shape. Figure 6 demonstrates how such a phenomenon arises. 
(a) (b) 
Figure 6: Electrospray jets in (a) an instance of wetting, and (b) stable mode. 
 In order to address such an issue, the primary strategy is to draw flow away from the sides 
of the nozzle and towards the center of the inner diameter. This was achieved using a combination 
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of two methods: applying a hydrophobic coating on the nozzle, or inserting a conductive needle 
that would draw the jet towards its tip, which is concentric with the inner diameter of the nozzle. 
 
2.3. Chemical Properties of Solvents 
 Miscibility 
 In molecular context, chemical concepts suggest that, in a binary solvent system, two 
solvents are miscible or immiscible to each other due to the geometry of the molecules of the two 
solvents. Common knowledge dictates that two nonpolar solvents are miscible and that two polar 
solvents are also miscible, but a polar and a nonpolar solvent are immiscible with each other. 
 However, in certain cases, the miscibility of two solvents may not be as clear-cut as being 
entirely soluble or insoluble, as some of the solvents used in this study have both polar and 
nonpolar components. A situation could arise wherein miscibility could only occur at certain ratios 
of the two solvents. Immiscibility occurs at a so-called miscibility gap, wherein at lower 
temperatures, it is highly likely that the two solvents coexist as two distinct phases in the same 
container. (17-18) Oftentimes, the miscibility gap occurs at low ratios of solutions, where the 
composition of one solvent does not clearly dominate over the other, as demonstrated in Figure 7, 
where mixtures of nitrobenzene in hexane has been used as an example. (18) 
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Figure 7: Phase diagram demonstrating miscibility gap present in mixtures of hexane (primary solvent) 
and nitrobenzene (secondary solvent) across different temperatures and compositions, at 1 atm presssure. 
The miscibility gap area is indicated by P = 2. 
 In order to circumvent such an issue, the binary solvent systems utilized in this study are 
mixed in ratios of at least nine-to-one, so as to ensure miscibility, regardless of molecular structure. 
In fact, such a ratio is also favorable with regards to the thermodynamic properties of the solution, 
which is to be discussed later. 
 Moreover, beyond composition, other parameters such as vessel pressure and temperature 
could be modified to influence the solubility of the two solvents with each other, but due to 
experiments being conducted largely at room temperature, such parameters have easily been 
overlooked in favor of working with the compositions of the solvent instead. 
 Thus, in this study, different pairings of organic solvents were used: water in ethanol; 
dimethyl sulfoxide (DMSO) in ethanol; and acetone in ethanol. 
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 Solubility of Docetaxel in Solvents 
 For the most part, docetaxel is almost entirely insoluble in water. However, at low weight 
percentages, docetaxel is soluble in a wide variety of organic solvents, including dimethyl 
sulfoxide and ethanol. According to LC Laboratories, the company from which the docetaxel used 
in this study was obtained, the saturation point for docetaxel in DMSO occurs at 200 mg/mL, while 
the saturation point for docetaxel in ethanol occurs at 100 mg/mL. (19) 
 Compatibility with Electrospray 
 The feasibility at which the solvents could be electrosprayed could be determined in terms 
of fluid conductivity. Multiple methods have been utilized for determining the compatibility with 
the electrospray, wherein smaller droplets, and therefore smaller powders, are produced when the 
drug is dissolved in a more conductive organic solvent.  
 One such method is through the determination of relative polarity of the organic solvents, 
which is influenced by factors such as ability to form hydrogen bonds, electronegativity of 
constituent atoms, and the net dipole moment of the molecules. (20) While also useful in 
determining other properties such as boiling and freezing points, the relative polarity is also a 
useful metric in determining the effectiveness of the solvents in the electrospray deposition 
process. Table 2 below lists the polarities of the various organic solvents utilized in this study, 
with water as the reference solvent. (21) 
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Organic Solvent Relative Polarity 
Acetone  0.355 
DMSO 0.750 
Ethanol 0.654 
Water 1.000 
Table 2: Relative polarities of selected organic solvents.  
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Chapter Three: Mass and Thermal Transport 
3.1. Overview 
 In general, the entire electrospray deposition process can be divided into three different 
processes: the formation of the jet within the neighborhood of the nozzle, followed by the 
dissolution into monodisperse droplets, and concluded by the evaporation of the droplets. The last 
step of this process occurs simultaneously with the diffusion of the solute drug into individual 
particles, which is to be collected for future use. Each of these steps can be accounted for in terms 
of the rates at which they happen and the energy required to make them happen. 
 
3.2. Jet Dynamics 
 Solution Properties 
 For the solvents used throughout the study, there are but a few important parameters that 
dictate the overall behavior of electrospray deposition. These properties are all dictated by polarity, 
as described earlier in Section 2.3.3. Among these properties include density ρ, surface tension γ, 
dynamic viscosity µ, electrical conductivity k, and dielectric constant ϵ. In the deposition process, 
these four properties play a huge role in governing the vital facets of the overall formation of the 
drug particles, including droplet size, solvent evaporation, and nucleation of the drug. Table 3 
below lists the said properties for the four primary solvents discussed in this study at room 
temperature. (22) 
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Organic 
Solvent 
Density 
(ρ, g/mL) 
Surface Tension 
(γ × 103, N/m) 
Dynamic Viscosity 
(µ × 103, N∙s/m2) 
Electrical 
Conductivity 
(k × 109, S/cm) 
Dielectric 
Constant 
(ϵ) 
Acetone 0.790 23.30 0.33 5.0 20.6 
DMSO 1.101 43.70 2.00 2.0 46.6 
Ethanol 0.789 22.40 1.08 1.4 22.3 
Water 0.998 72.75 0.89 5.0 × 108 79.7 
Table 3: Relevant Properties for organic solvents. handbook of organic solvents 
 Due to the presence of charge in the liquid solution, which is provided beforehand by a 
certain range of voltages from a voltage source, the outflow of solution exiting the nozzle will 
naturally converge towards a certain point, which is the tip of the cone jet. The convergence 
towards this central point leads to an accumulation of charge, which translates to an electromotive 
force. Coupled with the inertia presented by the mass flow rate, these two forces overcome the 
surface tension that keeps the jet bound together. Such a phenomenon is accounted for by the 
Weber number, which is defined by 
𝑊𝑒 =
𝜌𝑣2𝑙
𝛾
 
where ρ is density, v is velocity (assuming constant cross-section area of flow), and l is the 
characteristic length along the jet. (23) 
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 The Weber number, in other words, is simply the ratio between the inertia of the fluid and 
its surface tension. At a certain vertical length of the cone jet, We = 1. Here, the jet dissociates into 
a series of monodisperse droplets, as shown in Figure 8. (15) 
 
Figure 8: Breakup of jet into droplets. 
  
3.3. Solvent Evaporation 
 The next step that follows the breakup of the cone jet and droplet formation is the 
evaporation of the droplet, which occurs simultaneously with the nucleation and growth of the 
solid drug into the sought-after particles. 
 Evaporation Rate for Single Solvent System 
 For a single solvent system, the time profile at which the liquid droplet evaporates in a 
linear manner. The overall time profile at which a droplet evaporates is dependent on both the 
properties of the solution and the diameter of the droplet, and is defined by the d2 law: 
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𝑑(𝑡) = 𝑑0
2 − 𝜅𝑡 
where d0 is the initial droplet diameter and κ is an evaporation rate that is dependent on the single 
solvent and t is the time and d(t) is the droplet diameter at time t. As described earlier, the initial 
droplet size itself is highly dependent on both chemical and electronic properties of the individual 
solvent. (24) 
 The evaporation rate κ is highly dependent on the surface tension of the solvent, as well as 
the density and temperature, which is assumed to be constant throughout the process. Vehring, et 
al, defines this constant as 
𝜅 =
8𝐷𝜌𝑔
𝜌𝑙
ln (
1 − 𝑌∞
1 − 𝑌𝑠(𝑇𝑒)
) 
where D is the diffusion coefficient of the solvent, Y∞ is the concentration of the solvent vapor at 
a very large distance away from the droplet (assumed to approach zero), Ys(Te) is the concentration 
of the solvent vapor at the surface of the droplet at some steady-state temperature Te, ρg is the 
density of gas (assumed to be air in this case), and ρl is the density of the solvent. (25) 
 From there, the rate at which the droplet shrinks in terms of diameter can also be 
approximated by algebraically rearranging the equation presented above when d(t) = 0, which 
yields 
𝑡𝑒𝑣𝑎𝑝 =
𝑑0
2
𝜅
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 Evaporation Rate for Binary Solvent System 
 For a binary solvent system, the rates at which the solvent evaporates occurs in two stages: 
a fast evaporation stage, in which the solvent with the smaller surface tension evaporates first, then 
followed by a slow evaporation stage, in which the remaining solvent evaporates. Due to the 
intermolecular forces present between the two solvents, the total time at which the entire solvent 
system evaporates cannot be the sum of the evaporation times of the individual solvents as droplets 
that are electrosprayed separately. Instead, factors such as miscibility and individual 
concentrations of the constituents are taken into account when calculating evaporation time. 
 Thus, for ease of calculation, the ratios between the two solvents are set such that an ideal 
solution is approximated. In other words, a large amount of one solvent is coupled with a small 
amount of the other solvent. In addition, the entire process is assumed to be of constant 
temperature. Mathematically, one can use mole fractions to approximate the radius of the overall 
droplet as a function of time, which Widmann and Davis defines as 
𝑑(𝑑𝑝
2)
𝑑𝑡
=
𝑑0
2
6𝑉𝑚
𝑑𝑉𝑚
𝑑𝑡
−
2𝑉𝑚
𝑅𝑇
∑𝐷𝑖𝑥𝑖𝛾𝑖𝑃𝑖
0
𝑖
 
where dp is the diameter of the droplet at some time t, d0 is the initial droplet diameter, Di is the 
diffusion coefficient for the solvent, xi is the mole fraction of the solvent, γi is the activity 
coefficient of the solvent, and Pi
0 is the vapor pressure for the solvent at room temperature, and Vm 
is the average molar volume of the components of the droplet, which is defined by 
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𝑉𝑚 =∑𝑥𝑖𝑉𝑖
𝑖
 
where Vi is the molar volume of the solvent. (26) 
 Here, a linear relation between the square of the droplet and time is still observed. However, 
adjustments have been made to account for mole fraction and the activity coefficients of the 
individual constituents towards the solvent. 
3.4. Particle Diffusion 
 Overview of Diffusion 
 While the solvent evaporates mid-drop, the solute (in this case, the drug) nucleates and 
then grows into a particle. The size of this particle increases over time and is strongly dependent 
on the concentration of the drug that is dissolved in the solvent system. The manner in which the 
particle diffuses, however, is completely independent of which solvent is present. Fortunately, in 
the case of the binary solvent system, the presence of a slow evaporation system due to a solvent 
with higher surface tension can prolong the diffusion stage. 
 Mathematical Interpretation of Diffusion 
 Regardless of the solvent system, the time profile that the drug undergoes can be first 
modelled using the d2 law. For simplicity, the full time it takes for a particle to form after being 
dissolved in the solution takes on a similar behavior as the evaporation time. Thus, the time it takes 
for the cancer drug to diffuse into an individual particle is loosely defined by 
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𝑡𝑑𝑖𝑓𝑓 =
𝑑𝑝
2
𝐷𝑠𝑦𝑠
 
where d is the particle diameter and Dsys is the diffusion coefficient of the system. Here, the particle 
diameter is dependent on properties of both the solute and the solvent system. (24) 
 Many different models have been used to approximate d, but it has been agreed upon that 
the particle diameter is strongly dependent on the concentration of the drug dissolved in the 
solvent. For example, Hartman, Brunner, et al, defines the particle diameter as 
𝑑𝑝 = 𝜙
1
3 (
𝜌𝜖𝑄3
𝛾𝐾
)
1/6
 
where ϕ is the concentration of the solute; and ρ, ϵ, Q, γ, and K are the density, dielectric constant, 
flow rate, surface tension, and electric conductivity, respectively, for the solvent. Fundamentally, 
the equation presented above shows that the particle diameter is largely a function of the cube root 
of the concentration and the square root of the flow rate, with the other properties of the solution 
exerting much smaller influence. (27) 
 
3.5. Competition between Evaporation and Diffusion 
 Ultimately, the final geometry of the particle is dependent on whether the evaporation 
process dominates or the diffusion process dominates. This competition is quantified by means of 
the Peclet number, which is defined as 
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𝑃𝑒 =
𝑡𝑑𝑖𝑓𝑓
𝑡𝑒𝑣𝑎𝑝
=
𝐾
𝐷𝑠𝑦𝑠
 
Simply put, the Peclet number is the ratio between the diffusion time and the evaporation time, 
which is also equivalent to the ratio between the evaporation and diffusion coefficients. (24-25) 
 If Pe > 1, the particle diffusion dominates the process. Here, unless terminated by landing 
at the collection area, the particle will continue to diffuse until its maximum particle diameter, 
which can occur even long after the solvent has fully evaporated. What results is the formation of 
particles that convey large voids within them. 
 On the other hand, if Pe = 1, neither the solvent evaporation nor diffusion dominates. At 
this condition, a morphology in which disk-shaped or hollow particles are expected to be observed 
in that the extent at which the particles have diffused is enough for cavities to form, while the 
overall quasi-spherical geometries observed remain intact. 
 Therefore, the optimal condition in the case of drug processing occurs when Pe << 1. Here, 
diffusion terminates well before the evaporation process concludes, thus leading the way for the 
formation of ideal aggregates. In this condition, spherical particles do form, and cavities are 
completely absent amongst the particles. 
 Studies performed by Vehring, Foss, et al, have verified such hypotheses. Figure 9 below 
shows a sampling of the morphologies of trileucine, a type of protein. (25) 
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(a) 
 
(b) 
 
(c) 
Figure 9: Morphologies of trileucine at (a) Pe << 1, (b) Pe = 1, and (c) Pe > 1.   
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Chapter Four: Experimental Methods 
4.1. Model Drug  
 Docetaxel (DTX), a drug that is primarily used in the treatment of cancer, is the main drug 
to be considered in this study. In some cases, the experiments were done in parallel with a similar 
drug known as paclitaxel (PTX). As shown in Figure 10, besides a few differences in functional 
groups – i.e. a acetyl group and a phenyl group for paclitaxel, which are replaced by a proton (in 
the form of a hydrogen atom) and a tert-butoxide group, respectively, for docetaxel – the two drugs 
convey similar structures and thus exhibit similar behavior with regards to how the disease is 
treated. (28) However, more thorough studies shows that out of the two, docetaxel is more effective 
in the treatment of various cancers. (2-4) 
 
Figure 10: Differences in molecular structure of paclitaxel and docetaxel. 
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 In this study, both docetaxel and paclitaxel were obtained from LC Laboratories at >99% 
purity. Based on the manufacturer, Table 4 below shows relevant properties for the two drugs used 
in this study. (19, 29) 
Drug Docetaxel Paclitaxel 
Molecular Formula C43H53NO14 C47H51NO14 
Molecular Weight 807.88 853.91 
Solubility in: 
(mg/mL) 
DMSO 200 200 
Ethanol 100 40 
Water <1 <1 
Table 4: Relevant properties of paclitaxel and docetaxel. 
 Due to the better efficacy, as well as due to a higher solubility in ethanol, docetaxel became 
the more preferred drug over paclitaxel when it came to performing experiments on the production 
of particles. 
 
4.2. Properties of Atomizer 
 Nozzle Geometry 
 In this project, two different aspects of the nozzle were explored upon: the geometry of the 
nozzle itself and if any accompanying devices were used to aid the nozzle in manipulating the 
shape of the flow.  
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 As a reference point, electrospray deposition was first done using nozzles with flat surfaces, 
as demonstrated in Figure 11a. In this study, standard 27 gauge needles and 30 gauge needles were 
used as the baseline nozzles. During such a regime, it was discovered that the surface tension of 
the solution caused the liquid to be attracted to flat tip of the nozzle, which eventually led to the 
fluid rising up to the outer column of the nozzle tubing. What eventually resulted was an 
enlargement of the cone jet. In other words, a nozzle with a flat profile led to inconsistent jet 
formation. 
 In order to circumvent such an issue, one solution that was looked into was the usage of 
tapered needles, as illustrated in Figure 11b. In such a nozzle configuration, it is hypothesized that 
the absence of a flat surface forced a cone jet to be formed downwards. 
 Similarly, a second solution was proposed. As shown in Figures 11c and 11d, a tungsten 
wire with a diametric thickness of 80 µm was electro-etched in a similar way as the tapering of 
certain nozzles, thereby producing a pointed end. With the pointed end facing outward, the tip was 
positioned in such a way that the tip was concentric with the opening of the nozzle itself. In doing 
so, it has been hypothesized that the tungsten wire will direct the solution towards the center of the 
nozzle, thereby producing a cone jet with the aid of the tungsten needle. 
 The electro-etching was achieved by using the tungsten wire as the anode, while a small 
bar made of carbon was used as the cathode. The carbon bar was immersed in the electrolyte, 
which a solution where Ossila Hellmanex III, a cleaning substance with similar properties as 
sodium hydroxide, was diluted with deionized water down to a concentration of 1 vol.%. Using 
the Atten AFT20B Function Wave Generator to produce a sinusoidal signal, and the Accel 
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Instruments TS-200 as the power source, alternating current with an amplitude of 3 kV and a 
frequency of 3 kHz were applied to both the tungsten anode and the carbon cathode. While the 
carbon cathode remained immersed in the electrolyte, the tungsten anode was raised and lowered 
about 1-2 mm into the electrolyte for around five to ten minutes to create a pointed tip. 
(a) (b) (c) (d) 
Figure 11: Schematic of (a) (standard) flat-surface nozzle; (b) tapered-surface nozzle; (c) flat-surface 
nozzle with tungsten needle; and (d) tapered-surface nozzle with tungsten needle. 
 Throughout the study, nozzles of various inner diameters were considered, with the main 
focus of using nozzles of smaller diameter in order to achieve droplets, and in turn, particles, of 
smaller size, as prescribed in earlier sections. 
 Nozzle Materials 
 Beyond the shape and size of the nozzle, material properties were also considered in the 
process of determining optimal conditions for producing the desired particles. As a reference point, 
stainless steel was primarily used. From there, the issue of the solution wetting arose, in which the 
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cone jet was disrupted due to the fluid clinging to the nozzle itself before being broken up into 
droplets. Eventually, this led to the drug solidifying onto the nozzle, thereby introducing a clog 
that further disrupted the formation of the stable jet necessary to make particles of consistent shape 
and size.  
 To remedy such a problem, two avenues were considered: changing the material of the 
nozzle, as well as introducing a hydrophobic coating. With regards to materials selection, the use 
of fused silica nozzles were explored. More specifically, PicoTip Emitter SilicaTip tapered nozzles 
sized at an inner diameter of 30 µm were used for all experiments regarding the use of fused silica 
needles.  
 As for coatings, polydimethylsiloxane (PDMS) was primarily applied at the tips of both 
stainless steel and fused silica nozzles. (30) The PDMS was obtained from Wacker Chemie AG in 
the form of SILRES H62-C silicone resin. After the application of the coating, the needles were 
then heated for one hour at 230 °C using the TRO480BS 4-Slice Toaster Oven from Black & 
Decker. 
 Summary 
 Ultimately, the table below shows the specifications of all of the possible configurations of 
nozzle material, inner diameter, coatings, geometry, and needle additives that are used throughout 
the study. While not all combinations were utilized for deposition, some key differences in nozzle 
configurations were explored in the study, including the presence of a concentric needle. 
Throughout the remainder of the paper, the type of nozzle configuration used shall be referred to 
by their numbers prescribed in the first column of Table 5. 
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Needle # 
Inner 
Diameter 
(ID, µm) 
Nozzle 
Geometry 
80 μm 
Tungsten 
Needle 
Material 
PDMS 
Coating 
Notes 
1 160 Flat No Stainless Steel No 
30 g nozzle 
2 160 Flat No Stainless Steel Yes 
3 160 Flat Yes Stainless Steel No 
4 160 Flat Yes Stainless Steel Yes 
5 160 Tapered Yes Stainless Steel No 
6 160 Tapered Yes Stainless Steel Yes 
7 100 Flat No Stainless Steel Yes 
100 µm 
stainless steel 
nozzle 
8 100 Flat Yes Stainless Steel Yes 
9 100 Tapered No Stainless Steel Yes 
10 100 Tapered Yes Stainless Steel Yes 
11 30 Tapered No Fused Silica No 30 µm ID silica 
nozzle 12 30 Tapered No Fused Silica Yes 
Table 5: Nozzle configurations used throughout the study. 
  
4.3. Solution Properties 
 Preparation of Stock Docetaxel Solutions 
 With regards to preparation of the solvent, an Accumax JE-507124 measuring pipette was 
used to mix dimethyl sulfoxide into ethanol in a 25 mL vial with a nine-to-one volume ratio, so as 
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to produce a solvent that is 10 vol. % DMSO and 90 vol. %. Using a Veritas M124A weighing 
scale, vitamin E TPGS, a solid, was measured onto an empty vial. Serial dilution was then utilized 
to measure enough of the liquid mixture in such a way that a solvent containing 0.05 wt. % vitamin 
E TPGS is prepared. 
 From there, the weighing scale was used to measure enough docetaxel in a separate vial to 
produce a solution that entails 2 wt. % of the drug and the remainder of the weight consisting of 
the solvent.  
 Overall, the solution in which 2 wt. % docetaxel dissolved in a solvent consisting of 0.05 
wt. % vitamin E TPGS mixed into 10 vol. % DMSO and 90 vol. % ethanol was considered the 
base solution from which experiments will be run. Additives are introduced later on to serve as 
variables that may affect particle morphology.  
 Fluid Conductivity 
 Previous literature has shown that the addition of trace amounts of salt to a solution has the 
capability to boost its conductivity in reference to electrospray atomization. (24) Such an increase 
can be quantified by means of measuring the output current during sample collection. In this study, 
the concept of solution conductivity was explored upon to determine its effects on the shape and 
size of deposited powders.  
 For all solutions containing the sodium salt, the additives were incorporated into the stock 
docetaxel solution by first dissolving 1 wt. % sodium salt in deionized water. From there, various 
amounts of the saline solution were transferred onto the stock docetaxel solution by means of 
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pipette. However, before electrospray deposition, the electrical conductivity of the solution was 
determined by using an ohmmeter capable of measuring in the order of megaohms, with two 
outgoing alligator clips attached to two 30-gauge needles providing the surface S described in 
Figure 12 below. (31)  
 
Figure 12: Schematic of the method used to determine electrolytic conductivity of solutions. 
 In the preliminary stages of the study, three different concentrations of salt were 
considered: no salt, 0.03 wt. % (300 ppm), and 0.05 wt. %. (500 ppm). However, the 0.05 wt. % 
level of salt additive was phased out due to producing results that are extremely similar to that of 
the 0.03 wt. % level of salt additive. It has been determined that the latter two concentrations of 
salt were relatively similar in terms of order of magnitude, so the study was committed to using 
either no salt or 0.03 wt. % salt. 
 Surfactants 
 After experiments were performed in solutions regarding the presence or lack of sodium 
salt, additional experiments were performed pertaining to whether or not the TPGS additive should 
remain included or not. Thus, four different solutions were used with regards to experimenting 
with omitting the surfactant are as follows: 
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 Solution 1: No sodium salt or vitamin E TPGS added 
 Solution 2: No sodium salt, but 0.05 wt. % vitamin E TPGS added 
 Solution 3: 0.03 wt. % sodium salt added, but no vitamin E TPGS 
 Solution 4: Both 0.03 wt. % sodium salt and 0.05 wt. % vitamin E TPGS added 
 Out of the four, upon determination of which solution works best, a second series of 
experiments were performed with regards to nozzle and needle properties. 
 
4.4. Deposition Conditions 
 Electrospray Conditions 
 Through both literature and preliminary experimentation, it has been discovered that the 
best way to produce finer particles of the drug was to minimize the size of the droplets being 
produced by electrospray. In order to do so, several avenues were considered: increasing the 
applied voltage, increasing the working distance, and decreasing the flow rate. However, each 
option has its maximum (or minimum for the flow rate) allowable value, as exceeding such 
thresholds can reduce or even eliminate the jet stability needed to consistently produce 
monodisperse droplets.  
 Ultimately, electrospray parameters were fixed at flow rates of either 1.0 µL/min or 0.5 
µL/min were adapted, with an applied voltage ranging from 2.5 kV – 3.0 kV. The working distance 
was established to between 3 cm and 4 cm, with significant changes were observed upon the slight 
variation in working distance.  
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 Two different avenues for particle collection were utilized thoroughly: small (i.e. 
approximately 2 cm in diameter) disks of aluminum foil in earlier studies, and roughly 1 cm × 1 
cm squares of silicon wafers in later studies. The substrate at which the particles were collected 
exhibited no signs of reacting with the drug itself, and had therefore no effect on the particle 
morphology itself. 
 Thermal History 
 Experiments with the variation of thermal history were performed by placing silicon wafer 
collection chips on top of a Cole-Parmer StableTemp heat plate. Preliminary experiments were 
performed to determine if any increase in temperature had any effect on particle morphology. In 
this earlier study, a docetaxel solution (same concentrations as previous solutions) containing 0.05 
wt. % salt and 0.05 wt. % vitamin E TPGS was electrospray deposited using Nozzle 11 at a flow 
rate of 1.0 µL/min and a working distance of 4 cm. Two different temperature levels were then 
considered: room temperature (20 °C) and 70 °C 
 In later stages of the study, the concept of thermal history was re-visited upon the discovery 
of better electrospray conditions. In the later stages, experiments were largely performed with 
Solution 3 being the main solution under study. Two different temperature stages were considered: 
room temperature (20 °C), and 45 °C. To eliminate additional variables, Needle 8 in the catalog 
prescribed above was primarily used, along with a flow rate of 0.5 µL/min and similar working 
distances and applied voltage.  
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4.5. Characterization of Particle Morphology 
 After particle collection, the silicon wafers were then characterized by means of scanning 
electron microscopy (SEM). In order to achieve this, the wafers were first sputter-coated using the 
Emitech K550X Sputter Coater at a current of 20 nA for approximately two minutes. From there, 
the particles themselves were viewed using the Zeiss ULTRA-55 FEG SEM, which was provided 
by UCF’s Materials Characterization Facility.  
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Chapter Five:  Results and Discussion 
5.1. Solution Properties 
 Electrolytic Conductivity 
 To compare the effectiveness of salt in increasing the conductivity of the particles, which 
is a significant component in reducing the overall size of the electrosprayed particles, Solutions 2 
and 4 as described in Section 4.3.3 were deposited and compared to each other. In this case, the 
solutions were prepared using paclitaxel as opposed to docetaxel, though the differences in 
behavior and particle morphology were considered negligible, as the two drugs are almost identical 
in molecular structure with slight differences in substituents. To eliminate other variables, the two 
solutions were electrosprayed in separate trials using Nozzle 12 as described in Section 4.2.3 at a 
flow rate of 0.5 μL/min at room temperature, with a working distance of 3 cm and an applied 
voltage of 2.5 – 3 kV. 
 Before SEM characterization was performed on the deposited particles, a conductivity test 
was performed as described in Section 4.3.2, with the results listed in Table 6. The two fluids were 
compared to ethanol, which served as the control group for the test. 
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Fluid Resistance Electrospray Current 
Ethanol 9.5 MΩ – 
Solution with no NaCl 1.74 MΩ 33.5 nA 
Solution with 0.03 wt.% 
NaCl 
0.03 MΩ 124 nA 
Table 6: Measured conductivities of electrosprayed solutions, compared in terms of vitamin E TPGS 
presence. 
 As expected, the introduction of table salt to the solution, even at miniscule amounts, was 
substantial in decreasing the measured resistance between the two measurement electrodes by 
about two orders of magnitude. With regards to the current output measured in the electrospray 
deposition process, at constant voltage, the resistance is expected to be inversely proportional to 
the deposition current, and this is reflected increase in the current by a factor of about 3.70. The 
significant spike in the current is reflected in previous literature, in which the strong electrolytes 
that are sodium and chloride ions provided by the table salt are largely responsible for increasing 
the flow of charges in the circuit path established by the electrospray system. (24) 
 On the context of particle morphology, the increase in current has translated to an extensive 
reduction in the particle size of the paclitaxel particles. The SEM samples shown in Figure 13 
reflects such an observation in a visual manner, and is also quantified by the 95% confidence 
intervals presented in Table 7. 
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(a) 
 
(b) 
Figure 13: Morphology of docetaxel particles without the addition of vitamin E TPGS (a) no salt added, 
(b) 0.03 wt.% salt added. 
Solution Type Sample Size 95% CI of Particle Size, nm 
No NaCl N = 6 452.48 ± 36.53 
0.03 wt.% NaCl N = 6 134.92 ± 28.85 
Table 7: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without 
sodium salt. 
 As demonstrated through SEM characterization and a brief particle size analysis, the 
addition of a trace amount of table salt to the deposited solution had an indirect influence on 
substantially reducing the particle size down by a factor of around 3.25. However, besides the 
reduction in size, the introduction of additional electrolytes has also led to an aggregation of 
particles. In spite of much larger particles, the absence of the electrolytes from the table salt has 
translated to a much larger dispersion across the substrate. On the other hand, as demonstrated in 
Figure 13b, the introduction of salt has not only drastically reduced the particle size, but has also 
led to a more inconsistent particle distribution, wherein particles were more likely to form clusters 
with each other. Moreover, the manner at which these particles adhere to each other has often led 
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to the creation of a large network of aggregates, which provides a web-like appearance for the 
particle morphology on the micrometer scale. 
 One possible explanation for such a phenomenon is that, while the salt itself does not react 
with the cancer drug and make significant changes to the overall molecular structure, the ions 
themselves do embed with the drug molecules as the liquid solvent dries up, thereby increasing 
the intermolecular forces that exist from one particle to another. Additionally the more elongated 
shapes of each clusters could largely be due to trajectories of each particle as they diffuse from 
monodisperse droplets, as they all start out from the same point (the opening of the nozzle or the 
tip of the tungsten needle) and diverge from there. The presence of ions from the salt then exerts 
much greater influence when it comes to how the particles are positioned on the substrate. 
 Surfactant Presence 
 In a similar manner as to determining the effects of the presence of vitamin E TPGS 
towards particle morphology, the effects of adding or omitting the vitamin E surfactant was 
determined, for the first experiment, by first measuring the electrolytic conductivity of the solution 
using methods described in Section 4.3.2, which produced results tabulated in Table 8. For this 
experiment, Solution 1 and Solution 2, as described in Section 4.3.3, were compared to each other. 
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Fluid Resistance Electrospray Current 
Solution with no vitamin E 
TPGS 
1.74 MΩ 33.5 nA 
Solution with 0.05 wt.% 
vitamin E TPGS 
2.00 MΩ 38.0 nA 
Table 8: Measured conductivities of electrosprayed solutions, compared in terms of vitamin E TPGS 
presence. 
 As indicated by Figure 5-4, there was no significant difference in electrolytic conductivity 
between the two solutions, which is expected in that the surfactant, as a bulky organic molecule, 
is not expected to ionize in the same way that salt does. 
 From there, the two solutions were electrosprayed using Nozzle 12, as described in Section 
4.2.3, with a flow rate of 0.5 μL/min at room temperature, a working distance of 3 cm, and an 
applied voltage of 2.5 – 3 kV. 
 The SEM characterization in Figure 14 shows that, as for the morphology itself, there was 
no change overall shape of the docetaxel particles. In both the control and experimental groups, 
with no ions from the salt to expedite the droplet formation process via an increased current, the 
particles took on much larger sizes (i.e. a diameter of around 400-450 nm). 
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(a) 
 
(b) 
Figure 14: Morphology of docetaxel particles (a) no vitamin E TPGS added, (b) with 0.05 wt.% vitamin E 
TPGS. Neither solution has any added salt. 
 However, upon conducting a brief statistical analysis on the size of the individual particles, 
a slight but noticeable difference in size between the two sets of particles. The 95% confidence 
intervals presented in Table 9 shows that, on average, the solution with the surfactant present was 
approximately 46 nm larger than its surfactant-free counterpart. 
Solution Type 
Sample 
Size 
95% CI of Particle Size, nm Two-sample 95% CI, 
nm 
No vitamin E TPGS N = 6 406.25 ± 62.03 46.23 ± 64.27 
0.05 wt.% vitamin E 
TPGS added 
N = 6 452.28 ± 36.53 
Table 9: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without 
vitamin E TPGS. 
 This 50 nm difference may be attributed to the fact that the surfactant has naturally formed 
micelles around each drug particle, thereby naturally increasing the overall diameter of the 
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particles by a slight amount. Such results reflect how the vitamin E TPGS surfactant behaves 
around docetaxel and paclitaxel, as described by previous literature. (8) 
 In order to verify such a phenomenon, a second experiment was carried out, this time with 
the addition of 0.03 wt. % table salt (i.e. Solutions 3 and 4 as described in Section 4.3.3), similar 
to the procedures described to perform the previous experiment at the beginning of this section. A 
similar nozzle, flow rate, operating temperature, and working distance as the first experiment was 
used to remove other unnecessary variables. With the addition of salt, particles from both sets of 
deposited docetaxel were expected to be much smaller and, in terms of morphology, cluster 
together and create a web-like appearance, which is reflected in Figure 15. 
 
(a)  
 
(b) 
Figure 15: Morphology of docetaxel particles (a) no vitamin E TPGS added, (b) with 0.05 wt.% vitamin E 
TPGS. Both solutions contained 0.03% salt by weight. 
45 
 
Solution Type 
Sample 
Size 
95% CI of Particle Size, nm Two-sample 95% CI, 
nm 
No vitamin E TPGS N = 6 134.92 ± 28.85 40.85 ± 30.16 
0.05 wt.% vitamin E 
TPGS added 
N = 6 216.62 ± 28.03 
Table 10: 95% confidence intervals of the sizes of electrosprayed docetaxel particles, with and without 
vitamin E TPGS, for the solutions containing 0.03 wt.% salt. 
 As shown above in Table 10, the 95% confidence interval for the difference in particle 
sizes between the two sets of electrosprayed docetaxel particles, which was calculated to be around 
41 nm, was roughly similar to the difference obtained from the first experiment, in spite of the 
diminished margin of error. This roughly constant difference across two largely different particle 
sizes (between adding and omitting the saline solution) demonstrates that the micelles behave in a 
consistent manner regardless of the presence of the saline solution. 
 
5.2. Nozzle Properties 
 In this part of the study, the exploration of the concentric tungsten needle was performed 
with the main goal of being able to facilitate the formation of a stable jet, which can be indirectly 
measured by calculating the variation of the sizes of the particles produced. A smaller variation in 
particle size implies a better control of the stability of the cone jet. Here, such a claim was 
compared to the hypothesis that the addition of a concentric needle to a larger nozzle can achieve 
results that are similar to that of a standalone nozzle that is already small. 
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 Here, Nozzle 10 was compared to Nozzle 12 (as listed in Section 4.2.3) through separate 
electrospray depositions of Solution 3 (as described in Section 4.3.3) using the two nozzles. In 
both trials, the solution was deposited with a flow rate of 0.5 μL/min at room temperature. 
 A key characteristic in determining nozzle configuration is the clearances provided in 
which the solutions can pass through. For Nozzle 10, with an inner diameter of 100 μm and a 
concentric needle 80 μm in diameter, an opening in the form of an annulus that is 900π μm2 in area 
exists for the solution to pass through. On the other hand, Nozzle 12 yields an inner diameter of 
30 μm, which translates into a 225π μm2 opening. The effects of having the two different openings 
on the morphology of the docetaxel particles were recorded through SEM characterization 
provided in Figure 16 and a brief statistical analysis provided in Table 11. 
 
(a) 
 
(b) 
Figure 16: Morphology of docetaxel particles (a) electrosprayed using a PDMS-coated silica nozzle, 
having ID = 30 μm, (b) electrosprayed using a PDMS-coated stainless steel nozzle with concentric 
tungsten needle, which yielded a clearance of t = 20 μm. 
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Nozzle Configuration Sample Size 95% CI of Particle Size, nm 
Nozzle 10 (100 μm stainless 
steel nozzle with 80 μm 
tungsten needle, SAopen = 900π 
μm2) 
N = 9 110.50 ± 16.25 
Nozzle 12 (30 μm silica 
nozzle, SAopen = 225π μm2) 
N = 6 134.92 ± 28.85 
Table 11: 95% confidence intervals for particle sizes in the experiment involving the concentric tungsten 
needle. 
 Thus, in spite of Nozzle 12 (silica nozzle) having one-fourth the opening surface area for 
the fluid to pass through, it produced particles that is slightly larger than Nozzle 10 simply because 
of the fact that the needle present in Nozzle 12 exerts a lot of influence with the stabilizing of the 
jet. The needle, being made of tungsten, a highly conductive metal, attracts the solution molecules 
that flow through the much larger nozzle. These molecules, which have been charged beforehand 
to 2.5 – 3 kV from a voltage source, converge onto the tip of the tungsten nozzle, which provided 
a highly strong electric field due to the sharp point at the tip (i.e. an extremely small radius). In 
turn, this small convergence area led to smaller monodisperse droplets and, in turn, smaller 
docetaxel particles produced. 
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5.3. Thermal History 
 Particle Size Analysis 
 With regards to determining the effects of thermal history, two different experiments were 
carried out to ensure consistency. The first experiment, as noted earlier in Section 4.4.2, were 
carried out using a docetaxel solution entailing 0.05 wt. % salt and 0.05 wt. % vitamin E TPGS, 
with Nozzle 11 from Section 4.2.3 as the atomizer, and a flow rate of 1.0 μL/min. In this trial, two 
different temperature stages were used: room temperature (roughly 20 °C) and 70 °C, which is 
close to the boiling point of ethanol, the largest component in the electrosprayed solutions in terms 
of the percent composition. Figure 17 contains the SEM samples that were taken at the conclusion 
of the experiment.  
 
(a) 
 
(b) 
Figure 17: Morphology of docetaxel particles (a) electrosprayed at room temperature, (b) electrosprayed 
at a substrate heated to 70 °C 
 Table 12 lists the 95% confidence intervals of the particle sizes at the two different 
temperature stages. 
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Electrosprayed Temperature Sample Size 95% CI of Particle Size, nm 
Room Temperature (20 °C) N = 6 152.18 ± 49.68 
Heated (70 °C) N = 9 283.71 ± 102.73 
Table 12: 95% confidence intervals for particle sizes in the first experiment involving thermal history. 
 As for the second experiment, the solution chosen for study was Solution 3 from Section 
4.3.3, with Nozzle 8 from Section 4.2.3, and a flow rate of 0.5 μL/min. Here, two different 
temperature stages were also used: room temperature and 45 °C, which is chosen due to the fact 
that it approximately marks the halfway point between room temperature and the boiling point of 
ethanol. Figure 18 contains the SEM samples that were taken at the conclusion of the experiment.  
 
(a) 
 
(b) 
Figure 18: Morphology of docetaxel particles (a) electrosprayed at room temperature, (b) electrosprayed 
at a substrate heated to 45 °C 
 Similarly, 95% confidence intervals for the samples of the second experiment were 
prepared in Table 13. 
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Electrosprayed Temperature Sample Size 95% CI of Particle Size, nm 
Room Temperature (20 °C) N = 8 107.00 ± 20.24 
Heated (45 °C) N = 8 108.21 ± 19.83 
Table 13: 95% confidence intervals for particle sizes in the second experiment involving thermal history. 
 In the first experiment, the variation amongst the particle sizes were largely due to the fact 
that the experimental temperature of 70 °C is extremely close to the evaporation temperature of 
the ethanol. Here, the varied thermal history has a more competitive role as compared to the 
important electrospray properties, namely the flow rate and the size of the nozzle. At a flow rate 
of 1.0 μL/min and a nozzle cross-sectional diameter of 30 μm, there has been a tendency to 
particles that are much larger in terms of diameter (i.e. 150 – 300 nm). With such sizes, as well as 
a temperature level closer to the boiling point, the temperature of the substrate has a stronger 
influence on the appearance of the particles. As evidenced by the 95% confidence intervals, the 
docetaxel powders deposited at the higher temperature level exhibited a margin of error that is 
twice in size compared to that of the powders deposited at room temperature. 
 As for the second experiment, it is expected for the variation and differences in mean of 
the particle sizes between the control group and the experimental group to not be as pronounced 
as compared to the first experiment. This can be attributed to the fact that, in spite of a larger 
overall inner diameter for the nozzle (100 μm as opposed to 30 μm), the addition of the tungsten 
needle that is 80 μm in diameter has resulted in an annulus with a thickness, and therefore a net 
clearance, of 10 μm for the solution to pass through. Combined with the reduced flow rate and the, 
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the sizes at which the droplets were formed were expected to be smaller compared to that of the 
first experiment. However, for the second experiment, the extent at which the effects of thermal 
history has affected the size of the dry particles was not as prevalent as compared to the first 
experiment. In this case, the electrospray parameters and nozzle selection at which the docetaxel 
was deposited had more dominance over the effects of the particle size than the temperature of the 
substrate. As the two confidence intervals indicate, the difference between the mean and spread of 
the sizes of the two sets of particles are almost negligible for the second experiment. 
 Particle Geometry Analysis 
   
(a) (b) (c) 
Figure 19: Docetaxel particle electrosprayed at (a) room temperature, (b) 45 °C, and (c) 70 °C, with all 
other parameters kept constant. 
 The effects of an increase in substrate temperature, however, was more noticeable in terms 
of the shape of the dry docetaxel particles. As illustrated above in Figure 19, most of the dry 
docetaxel particles deposited at room temperature seem to convey the morphology of voided 
hemispheres. Additionally, the lowered temperature enabled the particles to aggregate together in 
clumps, thereby providing inconsistent particle distribution across the substrate. 
 Moving up to a substrate temperature of 45 °C, a rounder shape was more easily observed 
amongst particles. Most of the particles started to take on either the shape of a pill or a sphere, with 
flattened or holed disks becoming not as prevalent. At this temperature stage, however, 
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aggregation was still evident, though the aggregates themselves were more consistent in that the 
clumps were of the same size, and were more evenly spread as compared to the particles deposited 
at room temperature. 
 Lastly, at 70 °C temperature near the boiling point of the dominant solvent (ethanol), the 
spherical shape of the deposited particles became much more apparent. At this temperature level, 
the aggregation of multiple particles in clumps, which were observed at room temperature and at 
45 °C, was close to nonexistent. Instead, individual particles were more dispersed across the 
substrate, and could easily be told apart from each other in SEM characterization.  
 Such observations regarding particle shape and dispersion tendencies reflect the literature 
presented regarding particle morphology, wherein particles with a low Peclet number (Pe << 1) 
tend to be almost always spherical, whereas particles with a higher Peclet number (Pe > 1) tend to 
convey large voids and resemble incomplete spheres. The morphologies achieved through 
experimentation at the different temperature stages reflect such assertions presented by previous 
studies. However, further research may be carried out in the future to determine such a threshold.  
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Chapter Six: Conclusions 
 In summation, it has been determined that electrospray deposition is a promising conduit 
for the processing of bulk docetaxel and even paclitaxel into monodisperse nanoparticles. Through 
the electrospray atomizer’s ability to produce droplets at a consistent size and rate, these droplets 
can consistently diffuse into particles of consistent size and shape. And through manipulation of 
different parameters, ranging from electrospray parameters and nozzle properties (both material 
and geometric), to the solution properties (in terms of both composition and constituents present 
or absent), the exact geometry of the particles produced can be easily manipulated to desired 
characteristics. 
 Moreover, the binary solvent system proved to be a strong candidate mixture for the 
docetaxel to be dissolved in. Oftentimes, in current pharmaceutical markets, docetaxel and 
paclitaxel are often sold as powdered drugs that are dissolved in an alcoholic solution, usually 
methanol. (5) However, in this study, a mixture of solvents, with primary focus on pairing ethanol 
with DMSO, was utilized. With prolonged evaporation rates presented by the binary solvent 
system, one can gain better command of the particle diffusion process in terms of altering the 
Peclet number to one’s favor by altering other parameters instead, such as operating temperature. 
 However, one significant drawback that is prevalent in this study is the low yield of the 
desired drug particles. This can largely be attributed to the smaller flow rate that is necessary to 
produce particles at the desired nanoscale size. However, future studies could be performed to 
easily circumvent this issue, wherein the multiplexing of electrospray atomizers could be explored 
in greater detail. (32)  
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